FDA Approves First Drug for Friedreich’s Ataxia
Published on in CHOP News
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Published on in CHOP News
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Published on in CHOP News
The Friedreich’s Ataxia Center of Excellence at CHOP was awarded $1.275 million by the Friedreich’s Ataxia Research Alliance, Hamilton and Finneran families and the CureFA Foundation
Published on in CHOP News
This consortium will conduct the most extensive neuroimaging study for Freidreich's ataxia to date.
To date, the effects of exercise have not been studied in children with Friedreich’s Ataxia – until now.
Read morePublished on in Children's View
A rare degenerative disease strikes during childhood. A multimillion-dollar gift is fueling CHOP scientists’ search for a cure.
Published on in Neurosciences Update, International Update
Researchers rarely use the word "cure" when studying a rare disease with no approved therapies. At the Friedreich's Ataxia Center of Excellence, the word "cure" is now in the lexicon.
Published on in Children's View
The new Friedreich’s Ataxia Center of Excellence gives hope and education to Grace Haupt and patients just like her.
Published on in CHOP News
Donations from Friedreich’s Ataxia Research Alliance and the Hamilton and Finneran Families helps launch Penn Medicine/CHOP Center to improve research and care for Friedreich's Ataxia, a rare, degenerative disease.